
    
      Structure:

      Prospective, single center, randomized, double-masked, parallel treatment comparison study.
      Subjects will be randomized to one of the following treatment arms to be dosed bilaterally
      twice daily (BID) for the first dosing period and four times daily (QID) for the second
      dosing period:

        1. Prednisolone Acetate 1% ophthalmic suspension

        2. Prednisolone Acetate 0.12% ophthalmic suspension

        3. Loteprednol Etabonate 0.2% ophthalmic suspension

        4. Tears Naturale® II

      Duration:

      Approximately four (4) weeks

      Controls:

      Artificial Tears (Tears Naturale® II)
    
  